COMP360 psilocybin treatment in TRD
By COMPASS Pathways
This page summarises results from COMPASS Pathways' phase 2b trial of investigational COMP360 psilocybin treatment for treatment-resistant depression. The study assessed three doses and reported a significant reduction in depressive symptoms after 25mg with psychological support.